» Articles » PMID: 30851880

Fluorescence-guided Tumor Detection with a Novel Anti-EpCAM Targeted Antibody Fragment: Preclinical Validation

Abstract

Tumor-specific fluorescent imaging agents are moving towards the clinic, supporting surgeons with real-time intraoperative feedback about tumor locations. The epithelial cell adhesion molecule (EpCAM) is considered as one of the most promising tumor-specific proteins due its high overexpression on epithelial-derived cancers. This study describes the development and evaluation of EpCAM-F800, a novel fluorescent anti-EpCAM antibody fragment, for intraoperative tumor imaging. Fab production, conjugation to the fluorophore IRDye 800CW, and binding capacities were determined and validated using HPLC, spectrophotometry and cell-based assays. In vivo, dose escalation-, blocking-, pharmacokinetic- and biodistribution studies (using both fluorescence and radioactivity) were performed, next to imaging of clinically relevant orthotopic xenografts for breast and colorectal cancer. EpCAM-F800 targets EpCAM with high specificity in vitro, which was validated using in vivo blocking experiments with a 10x higher dose of unlabeled Fab. The optimal dose range for fluorescence tumor detection in mice was 1-5 nmol (52-260 μg), which corresponds to a human equivalent dose of 0.2-0.8 mg/kg. Biodistribution showed high accumulation of EpCAM-F800 in tumors and metabolizing organs. Breast and colorectal tumors could clearly be visualized within 8 h post-injection and up to 96 h, while the agent already showed homogenous tumor distribution within 4 h. The blood half-life was 4.5 h. This study describes the development and evaluation of a novel EpCAM-targeting agent and the feasibility to visualize breast and colorectal tumors by fluorescence imaging during resections. EpCAM-F800 will be translated for clinical use, considering its abundance in a broad range of tumor types.

Citing Articles

Potential Probes for Targeted Intraoperative Fluorescence Imaging in Gastric Cancer.

Martinelli S, Fortuna L, Coratti F, Passagnoli F, Amedei A, Cianchi F Cancers (Basel). 2025; 16(24.

PMID: 39766041 PMC: 11675003. DOI: 10.3390/cancers16244141.


Fluorescence-guided tumor visualization of colorectal cancer using tumor-initiating probe yellow in preclinical models.

Kim S, Kim J, Kim H, Chang Y, Kwon H, Lee J Sci Rep. 2024; 14(1):26946.

PMID: 39505985 PMC: 11542034. DOI: 10.1038/s41598-024-76312-1.


Tumour Marker Expression in Head and Neck Malignancies to Identify Potential Targets for Intraoperative Molecular Near-Infrared Imaging.

Lauwerends L, Zweedijk B, Galema H, Neijenhuis L, Dekker-Ensink N, Baatenburg de Jong R Mol Diagn Ther. 2024; 28(6):811-820.

PMID: 39251469 PMC: 11512873. DOI: 10.1007/s40291-024-00742-w.


A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.

Jeremiasse B, van Ineveld R, Bok V, Kleinnijenhuis M, de Blank S, Alieva M EMBO Mol Med. 2024; 16(7):1495-1514.

PMID: 38831131 PMC: 11251264. DOI: 10.1038/s44321-024-00084-4.


Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer.

Houvast R, Badr N, March T, de Muynck L, Sier V, Schomann T Eur J Nucl Med Mol Imaging. 2023; 51(8):2179-2192.

PMID: 37642704 PMC: 11178671. DOI: 10.1007/s00259-023-06407-w.